The head of Mylan will face lawmakers' questions at a hearing next week on steep price hikes for the company's life-saving EpiPen injector device.
Mylan CEO Heather Bresch and officials from the Food and Drug Administration will testify before the House Oversight and Government Reform Committee.
The Republican chairman of the committee and the panel's top Democrat said in a statement that there is "justified outrage" from families and schools struggling to pay for the emergency allergy shots. The price has grown to $608 for a two-pack, up more than 500 percent since 2007.
Reps. Jason Chaffetz of Utah and Elijah Cummings of Maryland said they will also examine ways to encourage greater competition in the EpiPen market.